Biotech Values

[poorgradstudent]

INCY:

I think probably a big component in the negative reaction* is not an erroneous comparison to Keytruda monotherapy at >49% in NSCLC, but a comparison to the abstract (ORRs in melanoma and RCC are lower than abstract) and to the Opdivo+Yervoy data in melanoma and NSCLC. The ORR of Keytruda+epacadostat is looking comparable, but numerically slightly lower than Opdivo+Yervoy.

Certainly may be a part of it. Some of the ORR data in the abstract were 100%... perhaps people thought INCY was BLUE and everyone would be cured forever.

As per usual, whenever we get new data, we end up waiting for the next set. Durability is going to be key, and the AE profile will factor in. At the least, the pembro + IDO's AE profile appears relatively mild... but still early days.